Mark N. Stein

11.9k citations
245 papers · 6.0k · 3 hit papers · h-index 41

Impact in

  • Oncology top 1%
    • Cancer Immunotherapy and Biomarkers
    • Cancer, Hypoxia, and Metabolism
    • Cancer Genomics and Diagnostics

Papers in

Mark N. Stein

236 papers receiving 5.9k citations

Mark N. Stein's Hit Papers

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial 2021 · 189 citations
1890+4+9Years since publication100200300400

Peers

Mark N. Stein
Comparison fields: 5 of 123
  • Oncology 2.0k
  • Cancer Research 1.1k
  • Pulmonary and Respiratory Medicine 1.8k
  • Immunology 811
  • Molecular Biology 2.0k
Replace Petri Bono with:
Petri Bono Finland
Young Kwang Chae United States
Jaime R. Merchan United States
Daniele Generali Italy
Michael J. Pishvaian United States
Sachio Fushida Japan
Lukas C. Heukamp Germany
Maurizio Martini Italy
De‐Chen Lin United States
Tetsuo Ohta Japan
Mark N. Stein relative to Petri Bono Finland Petri Bono's profile →
Citations per field
00.5×3.1×
Petri Bono · 1×
Citations per year

Countries citing papers authored by Mark N. Stein

Since Specialization
Citations

This map shows the geographic impact of Mark N. Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark N. Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark N. Stein more than expected).

Fields of papers citing papers by Mark N. Stein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark N. Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark N. Stein. The network helps show where Mark N. Stein may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark N. Stein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark N. Stein Line = papers co-authored together Mark N. Stein links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 245 papers — load more, or switch the sort, to bring in the rest.

#Work
1
A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors
Hit paper breakdown →
2012424
2 2016291
3 2010241
4 2017224
5 2009208
6
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
Hit paper breakdown →
2021189
7
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
Hit paper breakdown →
2021176
8 2017166
9 2012126
10 2018122
11 2010119
12 2019117
13 2009108
14 201391
15 201587
16 200886
17 201677
18 201966
19 201464
20 201863

About Mark N. Stein

Mark N. Stein is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Surgery, having authored 245 papers that have together received 6.0k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (59 papers), Cancer Immunotherapy and Biomarkers (57 papers), Renal cell carcinoma treatment (37 papers), Bladder and Urothelial Cancer Treatments (30 papers), Radiopharmaceutical Chemistry and Applications (21 papers), Cancer Treatment and Pharmacology (21 papers), Cancer Genomics and Diagnostics (20 papers) and Immunotherapy and Immune Responses (19 papers). The work is most often cited by research in Oncology (2.0k citations), Cancer Research (1.1k citations), Pulmonary and Respiratory Medicine (1.8k citations), Immunology (811 citations) and Molecular Biology (2.0k citations). Mark N. Stein has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Robert S. DiPaola, Eileen White, Susan Goodin, Kevin Bray, Grace L. Lu‐Yao, Charles G. Drake, Yu‐Hsuan Joni Shao, Simantini Eddy, Dmitri Dvorzhinski and Amit Mehta. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Annals of Oncology, Cancer Research and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact